Phenserine efficacy in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 4, 2010, Pages 1201-1208

  Winblad, Bengt ^a   Giacobini, Ezio ^b   Frölich, Lutz ^c   Friedhoff, Lawrence T ^d   Bruinsma, Gosse ^e   Becker, Robert E ^f,g   Greig, Nigel H ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Pharmaceutical Special Projects Group LLC   (United States)

^e Ciurem Pharma BV   (Netherlands)

^f Aristea Translational Medicine Corp   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholinesterase; Alzheimer clinical trial; Alzheimer's disease; amyloid peptide; amyloid protein precursor; cholinesterase inhibitor; phenserine

Indexed keywords

AMYLOID BETA PROTEIN; PHENSERINE; PLACEBO;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITION; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 79751501738     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101311     Document Type: Article

References (55)

1. Becker RE, Greig NH, Giacobini E. (2008) Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis 15, 303-325.
2. Lindner MD, McArthur RA, Deadwyler SA, Hampson RE, Tariot PN (2008) Development, optimization and use of pre-clinical behavioral models to maximize the productivity of drug discovery for Alzheimer's disease. In: Animal and Trans-lational Models for CNS Drug Discovery: Neurologic Disorders. McArthur RA, Borsini F, eds. San Diego: Academic Press p. 93-157.
3. Bartus RT, Dean RL 3rd (2009) Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurode-generative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl) 202, 15-36.
4. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG (2009) Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 5, 245-255.
5. Farlow MR, Cummings JL (2007) Effective pharmacologic management of Alzheimer's disease. Am J Med 120, 388-397. (Pubitemid 46627453)
6. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1, 1-31. (Pubitemid 37021521)
7. Selkoe DJ (2007) Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr Rev 65(12 Pt 2), S239-S243.
8. Hardy J (2006) Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3, 71-73.
9. Lee H-G, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid beta: the alternate hypothesis. Curr Alzheimer Res. 3, 75-80.
10. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3, 81-90.
11. Welander H, Frnberg J, Graff C, Sundström E, Winblad B, Tjernberg LO (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110, 697-706
12. Nimmrich V, Ebert U (2009) Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci 20, 1-12
13. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG (2010) Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem 285, 2506-2514.
14. Frykman S, Hur JY, Frnberg J, Aoki M, Winblad B, Nahalkova J, Behbahani H, Tjernberg LO (2010) Synaptic and endosomal localization of active gamma-secretase in rat brain. PLoS ONE 5, e8948.
15. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M.(2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.
16. Banwait S, Galvan V, Zhang J, Gorostiza OF, Ataie M, Huang W, Crippen D, Koo EH, Bredesen DE (2008) C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. J Alzheimers Dis 13, 1-16 (Pubitemid 351365623)
17. Pei JJ, Sjögren M, Winblad B (2008) Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. Curr Opin Psychiatry 21, 555-561.
18. Buccafusco JJ (2009) Emerging cognitive enhancing drugs. Expert Opin Emerg Drugs 14, 577-589.
19. Amijee H, Scopes DI (2009) The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J Alzheimers Dis 17, 33-47.
20. Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A (1995) Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 15, 3-31
21. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2, 281-290. (Pubitemid 40980186)
22. Al-Jafari AA, Kamal MA, Greig NH, Alhomida AS, Perry ER (1998) Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. Biochem Biophys Res Commun 248, 180-185 (Pubitemid 28418208)
23. Greig NH, De Micheli E, Holloway HW, Yu QS, Utsuki T, Perry TA, Brossi A, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT (2000) The experimental Alzheimer drug phenserine: pre-clinical pharmacokinetics and pharmacodynamics. Acta Neu-rol Scand Suppl 176, 74-84. (Pubitemid 32156174)
24. Klein J (2007) Phenserine. Expert Opin Investig Drugs 16, 1087-1097. (Pubitemid 47074163)
25. Thatte U (2005) Phenserine Axonyx. Curr Opin Investig Drugs 6, 729-739. (Pubitemid 40908878)
26. Becker RE, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Dev Res 12,163-195.
27. Rodda J, Morgan S, Walker Z (2009) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21, 813-824.
28. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tens-feldt T; Alzheimer's Disease Working Group (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
29. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98, 7605-7610. (Pubitemid 32567995)
30. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320, 386-396. (Pubitemid 46025753)
31. Lahiri DK, Alley GM, Tweedie D, Chen D, Greig NH (2007) Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. Neuromolecular Med 9, 157-168. (Pubitemid 47065543)
32. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC (1997) Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 46, 161-168. (Pubitemid 27214367)
33. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR Jr, Canfield CJ, Burford RG (2005) Anti-cholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2, 483-492. (Pubitemid 41277760)
34. Becker RE (2005) Lessons from Darwin: 21st century designs for clinical trials. Curr Alzheimer Res 2, 319-326.
35. Becker RE (2007) Lessons from Darwin: evolutionary biology's implications for Alzheimer's disease research and patient care. Curr Alzheimer Res 4, 458-467.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944 (Pubitemid 14076461)
37. Rosen WG, Mohs RC, Davies KL (1980) Pathological Validation of Ischemia in differentiation of dementia. Ann Neurol 7, 486-488. (Pubitemid 10073130)
38. Folstein M, Folstein S,McHugh PR(1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
39. Declaration of Helsinki, 1964 [as amended in Tokyo (1975), Venice (1983), Hong Kong (1989) South Africa ( 1996), Scotland ( 2000), with note of clarification on paragraph 29 added by the WMA General Assembly, Washington USA 2002)].
40. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364 (see Appendix A).
41. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of anti-dementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), 13-21.
42. Reisberg B, Schneider LS, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T (1997) Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines, Alzheimer Dis Assoc Disord 11 (Suppl 3), S8-18.
43. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1997) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S22-32.
44. Data on file (2004) Axonyx Corporation, New York, NY.
45. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT (1999) The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 10, 237-244. (Pubitemid 29224502)
46. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Lngström B, Nordberg A (2008) Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63, 621-631.
47. Becker RE, Greig NH (2008) Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 5, 346-357.
48. Cogger KO (2007) Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs. J Clin Psychopharmacol 27, 418-420. (Pubitemid 47075527)
49. Becker RE, Greig NH (2010) Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7(7), 642-651.
50. Schneider LS (2008) Issues in design and conductance of clinical trials for cognitive-enhancing drugs. In: Animal and Translational Models of Behavioural Disorders. McArthur RA, Borsini F, eds. Neurological disorders. Volume 2. New York: Elsevier.
51. Schneider LS, Lahiri DK (2009) The perils of Alzheimer's drug development. Curr Alzheimer Res 6, 77-78.
52. Axonyx press release (10/30/2001). http://findarticles.com/ p/articles/mi-m0EIN/is-2001Oct-30/ai-79540858, Accessed May 4, 2010.
53. Nordberg A (2010) Amyloid imaging in early detection of Alzheimer's disease. Neurodegener Dis 7, 136-138.
54. Sambamurti K, Prakasam A, Anitha S, Venugopa C, Cullen E, Zhou Y, Bruinsma G, Lahiri DK, Greig NH, Friedhoff L (2006) Oral phenserine tartrate treatment is associated with reduced plasma Aβ 1-42 in a phase I clinical study. In New Trends in Alzheimer's and Parkinson's Disorders: ADPD 2006, Fisher A, Hanin I, Memo M, Stocchi F, Eds. Medimond, Via Maserati 5, Bologna, Italy, pp. 571-575.
55. Mangaliasche F, Solomon A, Winblad B, Mecocci P and Kivipelto M (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9, 702-716.